

**Nova Scotia Provincial Pharmacare Programs**  
**Request for Coverage of Chronic Obstructive Pulmonary Disease (COPD)**  
**Therapy**

PATIENT INFORMATION			
PATIENT SURNAME	PATIENT GIVEN NAME	HEALTH CARD NUMBER	DATE OF BIRTH
PATIENT ADDRESS			
DIAGNOSTIC INFORMATION			
Post bronchodilator-FEV <sub>1</sub> (% predicted): _____		Post bronchodilator-FEV <sub>1</sub> /FVC ratio: _____	
MRC Dyspnea Scale Grade: _____			
<input type="checkbox"/> <b>Asthma/COPD (ACO) overlap</b> – Please provide supporting details (patient symptoms, risk factors, spirometry, etc.): _____ _____			
COPD Assessment Test (CAT) Score _____			
<input type="checkbox"/> Hospitalized for acute severe COPD exacerbation in last 12 months <input type="checkbox"/> Two or more moderate COPD exacerbations in the last 12 months requiring antibiotics/systemic corticosteroids			
► If spirometry can not be obtained, please provide the details why <b>AND</b> provide the MRC Dyspnea Scale grade to indicate COPD severity: Explanation: _____ _____			
REQUESTED THERAPY			
► <b>Section 1: Request for Long Acting Beta<sub>2</sub>-Agonist (LABA) Monotherapy:</b> <input type="checkbox"/> Serevent Diskus			
► <b>Section 2: Request for Long Acting Muscarinic Antagonist (LAMA) Monotherapy:</b> <input type="checkbox"/> Spiriva Respimat <input type="checkbox"/> Spiriva Handihaler <input type="checkbox"/> Incruse Ellipta <input type="checkbox"/> Seebri Breezhaler <input type="checkbox"/> Tudorza Genuair			
► <b>Section 3: Request for Long Acting Beta<sub>2</sub>-Agonist (LABA)/Inhaled Steroid (ICS) Monotherapy for Asthma/COPD Overlap:</b> <input type="checkbox"/> Advair <input type="checkbox"/> Symbicort <input type="checkbox"/> Breo Ellipta			
► <b>Section 4: Request for LAMA/LABA Dual Therapy: (combination of single agent LABA and LAMA will not be considered)</b> <input type="checkbox"/> Anoro Ellipta <input type="checkbox"/> Duaklir Genuair <input type="checkbox"/> Inspiolto Respimat <input type="checkbox"/> Ultibro Breezhaler <input type="checkbox"/> Has been on a LABA or LAMA for at least 1 month.    Inhaler: _____    Start date: _____			
► <b>Section 5: Request for LABA/ICS + LAMA or ICS/LAMA/LABA (combined in one inhaler)</b> <input type="checkbox"/> Advair <input type="checkbox"/> Symbicort <input type="checkbox"/> Breo Ellipta LAMA (please specify) _____ <input type="checkbox"/> Trelegy Ellipta (Start Date if applicable): _____ <input type="checkbox"/> Breztri Aerosphere (Start Date if applicable): _____			
<b>For Triple Therapy:</b> <input type="checkbox"/> Symptomatic despite at least two months of treatment with LABA/ICS or LAMA/LABA.			
<b>Details of prior inhaler therapy:</b> Inhaler: _____ Start Date: _____ Inhaler: _____ Start Date: _____			
<b>PRESCRIBER NAME &amp; ADDRESS:</b>  _____ _____ _____		_____ _____ _____	
LICENCE #		PRESCRIBER SIGNATURE	
		DATE	

If you need assistance, please contact the Pharmacare Office at (902) 496-7001 or 1-800-305-5026

**Please Return Form To:** Nova Scotia Pharmacare Programs  
 P.O. Box 500, Halifax, NS B3J 2S1  
 Fax: (902) 496-4440

